Baxalta — BAML Global Healthcare Conference 2015
19 slides from Baxalta's conference presentation, Sep 17, 2015
Slide 1: The next step in our journey
Jeff Poulton CFO The next step in our journey BAML Global Healthcare Conference, 2015 September 17, 2015
Slide 2: Forward-looking statements
Statements included in this announcement that are not historical facts, including without limitation statements concerning our 10x20 ambitions and targets, our proposed combination with Baxalta Incorporated (“Baxalta”), and the timing and benefits thereof, including our 20x20 ambition that targets $
Slide 3: Cautionary statement and additional information
All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the exte
Slide 4: Our continuous transformation 2013-2015
Our continuous transformation 2013-2015 Becoming OneShire Step-change in performance Effective and efficient organization Set basis for long-term growth Investing to create further long-term value 2013 2014 2015 2016 2017 2018 2019 2020+ 2014-2020+ Building a leading global biotech company Creating
Slide 5: Why focus on rare diseases?
Why focus on rare diseases? Large opportunity for innovation Huge medical burden for patients and HC systems Over 7,000 diseases, of which only 5% have treatments Increasing share of regulatory approvals in US, EU and Japan Often accelerated development due to priority review and phase-skipping Life
Slide 6: Rare Diseases require unique capabilities – and ours are industry-leading
Rare Diseases require unique capabilities – and ours are industry-leading Commercial R&D Manufacturing Many un- or misdiagnosed patients Complex disease management Significant persistence and compliance challenges Challenging trial recruitment due to small populations Complex ethical questions – pla
Slide 7: Q2 2015: Progress towards becoming a leading global biotechnology company
Q2 2015: Progress towards becoming a leading global biotechnology company Strong US launch for NATPARA in HPT Continued strong growth for VYVANSE post BED launch GATTEX performing well; implementation of enhanced commercial plans GROWTH Double digit CER(1) product sales growth excluding INTUNIV Phas
Slide 8: Delivering double digit core product sales growth while investing for the future
Delivering double digit core product sales(1) growth while investing for the future Core product sales excluding INTUNIV growing 12% on a constant exchange rate basis(2)(4) Continuing to make significant investment in expected future growth drivers: VYVANSE BED, GATTEX/REVESTIVE and NATPARA H1 Non G
Slide 9: Positive momentum in VYVANSE Rx trends continues post BED approval
GROWTH Since launch of VYVANSE for BED in Q1, we have seen a steady increase in our above market performance resulting in YoY share growth The ADHD “summer dip” has not been as steep as previous years Executing in the back-to-school season while maintaining our adult momentum Source: weekly IMS data
Slide 10: Leveraging Shire's capabilities to grow GATTEX
Leveraging Shire’s capabilities to grow GATTEX New field based patient support role (Onboarding & Access Specialist/OAS) to aid with initiation of therapy OAS also supports early experience with GATTEX Legacy NPS GATTEX sales team dedicated to converting patient leads Over 500 patients on therapy in
Slide 11: Strong start for Natpara in the US
Strong start for Natpara in the US NATPARA launched in the US April 1, 2015 NATPAR submitted in EU December 2014; filing on track with estimated approval in Q1 2016 Positive response from Endocrinologists to NATPARA Over 70% of target US physicians REMS(1) trained (~1,900) as at end of June 2015 App
Slide 12: Late stage pipeline poised to deliver
Late stage pipeline poised to deliver Preclinical Phase 1 Phase 2 Phase 3 Registration TH / GCH1 GenePod Parkinson’s Subset 26 Research Programs SHP608 Dystrophic E.Bullosa SHP631 Hunter Syndrome SHP624 Heme B Gene Edit SHP623 (rC1-INH) HAE prophylaxis SHP611 MLD (Ph 1/2) SHP616 (CINRYZE SC) HAE Pro
Slide 13: Lifitegrast has potential to be the 1st product to treat Dry Eye Disease
Lifitegrast has potential to be the 1st product to treat signs and symptoms of Dry Eye Disease (DED) Lifitegrast (SHP606) under FDA review for the treatment of the signs and symptoms of dry eye disease; PDUFA date October 25, 2015 No advisory committee meeting has been scheduled by FDA for the curre
Slide 14: Proposed combination with Baxalta
Proposed combination with Baxalta
Slide 15: Proposed combination would create the global leader in rare diseases
Proposed combination would create the global leader in rare diseases with compelling financials and strong outlook The global leader in rare diseases ~$20B in product sales by 2020 (“20x20”) Multiple $1B+ high-value rare diseases franchises with substantial barriers to entry Complementary expertise
Slide 16: Benefits accrue to shareholders of both companies
Benefits accrue to shareholders of both companies Baxalta shareholders expected to benefit from Immediate significant premium Acceleration and de-risking of Baxalta’s strategy Enhanced growth trajectory Opportunity to participate in a dynamic growth platform Shire shareholders expected to benefit fr
Slide 17: Questions and Answers
4 Questions and Answers/ |)
Slide 18: Investor relations contacts
Investor relations contacts International: Sarah Elton-Farr Souheil Salah T: +44 1256 894157 T: +44 1256 894160 E: seltonfarr@shire.com E: ssalah@shire.com North America: Matt Osborne T: +1 781 482 9502 E: mattosborne@shire.com
Slide 19: Non GAAP financial measures
This presentation contains financial measures not prepared in accordance with US GAAP. These measures are referred to as “Non GAAP” measures and include: Non GAAP operating income; Non GAAP net income; Non GAAP diluted earnings per ADS; effective tax rate on Non GAAP income before income taxes and e